Diskussion zu Advaxis - 500 Beiträge pro Seite
eröffnet am 29.12.09 20:21:05 von
neuester Beitrag 16.07.13 17:51:51 von
neuester Beitrag 16.07.13 17:51:51 von
Beiträge: 73
ID: 1.155.052
ID: 1.155.052
Aufrufe heute: 0
Gesamt: 3.342
Gesamt: 3.342
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 2188 | |
| heute 16:05 | 1590 | |
| heute 11:20 | 1509 | |
| heute 14:03 | 1448 | |
| heute 09:52 | 1150 | |
| heute 15:11 | 1105 | |
| vor 1 Stunde | 1068 | |
| vor 53 Minuten | 790 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.161,01 | +1,36 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3500 | +1,14 | 60 | |||
| 5. | 4. | 168,29 | -1,11 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,7950 | +6,91 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 31 |
Feedback
Pending clinical trials ... für Ende Januar und sollte bei so manchem Promoter auf der Liste stehen.
ist schon irre, wie unbekannt dieser Wert zu sein scheint.
Phase II Trial beginnt
http://www.marketwatch.com/story/advaxis-initiates-phase-ii-…
Phase II Trial beginnt
http://www.marketwatch.com/story/advaxis-initiates-phase-ii-…
der heutige Kursanstieg liegt wohl an der Ankündigung der HV mit der Genehmigung neuen Kapitals über Optionen ....
Advaxis to Host Investigators Meeting for ADXS11-001 Cervix Cancer Trial in Mumbai, India
Twenty of India’s Leading Oncologists to Attend | Meetings Set for May 7 – 8, 2010
Press Release Source: Advaxis, Inc. On Monday May 3, 2010, 10:00 am
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS - News), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will host an investigator’s meeting in Mumbai, India with twenty (20) of the country’s leading oncologists. The meeting is set for May 7-8, 2010 and will help prepare for the initiation of a multicenter study of their lead compound, ADXS11-001 for the treatment of advanced, metastatic cervix cancer in women who have failed cytotoxic therapy.
Investigators from Apollo Hospitals Research Foundation, Tata Memorial Centre, Chittaranjan National Cancer Institute and other sites of clinical excellence will discuss Advaxis’ work, the experimental protocol to be conducted and the execution of the clinical trial.
“Cervix cancer is a leading cause of mortality in Indian women,” said Advaxis Executive VP of Science and Operations Dr. John Rothman. “If the efficacy signal we observed in our Phase 1 study in this patient population is repeated in this larger study, then ADXS11-001 may represent an important agent for the treatment of a disease state for which no effective therapy currently exists. We will also be investigating the use of our immunotherapy in combination with chemotherapy in this trial. Combining immune and cytotoxic treatments is a very interesting and important area of contemporary cancer research.”
Later during the week, Dr. John Rothman will lecture at the Chitteranjan National Cancer Institute and Chhatrapati Shahuji Maharaj Medical University –formerly, King George's Medical University.
About the ADXS11-001 Immunotherapy
ADXS11-001 is a therapeutic vaccine that treats human papilloma virus (HPV) related tumors. Unlike marketed prophylactic vaccines that require treatment prior to exposure to the virus, ADXS11-001 treats patients who have already developed cancer as a result of HPV infection. Today, HPV is the most prevalent sexually transmitted disease in the US and the cause of cervix cancer, 40% of head and neck cancer, as well as penile, vulvar and anal cancer. Other clinical trials are planned for this agent in 2010 including a trial in cervical intraepithelial neoplasia (CIN), and oropharyngeal head and neck cancer.
About The Advaxis Phase I Clinical Trial
This Phase I clinical trial was conducted in women with advanced cervix cancer that had progressed following cytotoxic therapy. In most cases, these women had been treated with multiple therapeutic modalities including surgery, radiation and chemotherapy. It is accepted that once these patients fail cytotoxic therapy there is little that can be offered to cure their disease or extend life. Historically, the median survival for these patients is approximately 180 days with only about 5% surviving one year. In the Advaxis Phase I clinical trial, the median survival was 347 days with 57% of patients surviving one year. More information on this clinical trial can be found in the published results of this trial (Vaccine 27 2009 3975–3983).
Twenty of India’s Leading Oncologists to Attend | Meetings Set for May 7 – 8, 2010
Press Release Source: Advaxis, Inc. On Monday May 3, 2010, 10:00 am
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS - News), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will host an investigator’s meeting in Mumbai, India with twenty (20) of the country’s leading oncologists. The meeting is set for May 7-8, 2010 and will help prepare for the initiation of a multicenter study of their lead compound, ADXS11-001 for the treatment of advanced, metastatic cervix cancer in women who have failed cytotoxic therapy.
Investigators from Apollo Hospitals Research Foundation, Tata Memorial Centre, Chittaranjan National Cancer Institute and other sites of clinical excellence will discuss Advaxis’ work, the experimental protocol to be conducted and the execution of the clinical trial.
“Cervix cancer is a leading cause of mortality in Indian women,” said Advaxis Executive VP of Science and Operations Dr. John Rothman. “If the efficacy signal we observed in our Phase 1 study in this patient population is repeated in this larger study, then ADXS11-001 may represent an important agent for the treatment of a disease state for which no effective therapy currently exists. We will also be investigating the use of our immunotherapy in combination with chemotherapy in this trial. Combining immune and cytotoxic treatments is a very interesting and important area of contemporary cancer research.”
Later during the week, Dr. John Rothman will lecture at the Chitteranjan National Cancer Institute and Chhatrapati Shahuji Maharaj Medical University –formerly, King George's Medical University.
About the ADXS11-001 Immunotherapy
ADXS11-001 is a therapeutic vaccine that treats human papilloma virus (HPV) related tumors. Unlike marketed prophylactic vaccines that require treatment prior to exposure to the virus, ADXS11-001 treats patients who have already developed cancer as a result of HPV infection. Today, HPV is the most prevalent sexually transmitted disease in the US and the cause of cervix cancer, 40% of head and neck cancer, as well as penile, vulvar and anal cancer. Other clinical trials are planned for this agent in 2010 including a trial in cervical intraepithelial neoplasia (CIN), and oropharyngeal head and neck cancer.
About The Advaxis Phase I Clinical Trial
This Phase I clinical trial was conducted in women with advanced cervix cancer that had progressed following cytotoxic therapy. In most cases, these women had been treated with multiple therapeutic modalities including surgery, radiation and chemotherapy. It is accepted that once these patients fail cytotoxic therapy there is little that can be offered to cure their disease or extend life. Historically, the median survival for these patients is approximately 180 days with only about 5% surviving one year. In the Advaxis Phase I clinical trial, the median survival was 347 days with 57% of patients surviving one year. More information on this clinical trial can be found in the published results of this trial (Vaccine 27 2009 3975–3983).
Trading Spotlight
der Kurs zieht seit einigen Tagen fest an. Heute kleine Pause. Die Aktie wird noch dieses Jahr der Kracher schlichthin
Advaxis Chairman/CEO Thomas A. Moore Presents at the BIO International Convention in Chicago, IL
Press Release Source: Advaxis, Inc. On Wednesday May 5, 2010, 1:00 pm EDT
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS - News), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, presents recent updates to the investment community concerning the company at the 2010 BIO International Convention in Chicago, IL.
About The BIO International Convention
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event’s opening speaker, G. Steven Burrill, addressed this year’s theme: “Biotech 2010- Life Sciences: Adapting for Success.” Past speakers include US Presidents George W. Bush and Bill Clinton, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan, and General Colin Powell, among many others.
About BIO
BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. We also represent state and regional biotech associations, service providers to the industry, and academic centers. The mission of BIO is to be the champion of biotechnology and the advocate for its member organizations - both large and small. For more information please visit: http://www.bio.org.
Press Release Source: Advaxis, Inc. On Wednesday May 5, 2010, 1:00 pm EDT
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Chairman/CEO Thomas A. Moore of Advaxis, Inc., (OTCBB: ADXS - News), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, presents recent updates to the investment community concerning the company at the 2010 BIO International Convention in Chicago, IL.
About The BIO International Convention
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event’s opening speaker, G. Steven Burrill, addressed this year’s theme: “Biotech 2010- Life Sciences: Adapting for Success.” Past speakers include US Presidents George W. Bush and Bill Clinton, Michael J. Fox, Sir Elton John, Her Majesty Queen Noor of Jordan, and General Colin Powell, among many others.
About BIO
BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals. We also represent state and regional biotech associations, service providers to the industry, and academic centers. The mission of BIO is to be the champion of biotechnology and the advocate for its member organizations - both large and small. For more information please visit: http://www.bio.org.
(OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, enrolled and has administered its initial dose to its third patient in its US Food and Drug Administration (FDA)-approved, phase II clinical trial in cervical intraepithelial neoplasia (CIN), commonly known as cervical dysplasia. This completes the enrollment of the vanguard group of patients for the first dosage group.
The clinical trial is a multicenter, randomized, placebo controlled, blinded clinical trial of ADXS11-001 –Advaxis’ lead immunotherapeutic candidate. This trial is being conducted at the site by Dr. Keith Aqua, M.D. at the Institute for Women’s Health & Body.
The clinical trial is a multicenter, randomized, placebo controlled, blinded clinical trial of ADXS11-001 –Advaxis’ lead immunotherapeutic candidate. This trial is being conducted at the site by Dr. Keith Aqua, M.D. at the Institute for Women’s Health & Body.
http://finance.yahoo.com/news/Advaxis-Secures-75-Million-bw-…
Finanzierung wurde durchgeführt
Ich setz Advaxis auf die watchlist
Finanzierung wurde durchgeführt
Ich setz Advaxis auf die watchlist
24.11.2010 16:01 Advaxis India Cervix Cancer Trial Begins Dosing
ADXS11-001 With and Without Chemotherapy for the Treatment of Advanced Progressive Cervix Cancer in Women Who Have Failed Cytotoxic Therapy
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed. This follows extensive review by the office of the Drugs Controller General of India, a blue ribbon commission of scientists convened to assess Advaxis clinical protocol, and a chemical and microbiological assessment of ADXS11-001 by the Indian Central Vaccine Research Laboratory at Kasuli. The initial patient is at the Dr. Kamakshi Memorial Hospital in Chennai.
The U.S. National Cancer Institute's Gynecologic Oncology Group has conducted 16 clinical trials in over 500 patients using various therapeutic regimens in this patient population and found the most effective regimen tested resulted in a median survival of approximately 6 months and a 1 year survival of 5%. By contrast, in a phase 1 study not designed to show efficacy, ADXS11-001 demonstrate a median survival of 347 days and a one year survival of 53%.
Because of the progressive and rapidly fatal nature of cervix cancer in women for whom cytotoxic treatment has failed, the design of this trial allows for a rapid appraisal of efficacy. Advaxis intends to report the effect of ADXS11-001 on survival versus these historical values in "real time", as the trial progresses, beginning in Summer, 2011.
About Advaxis Indian Phase II Trial of ADXS11-001
This trial differs from Advaxis phase I trial in this patient population in two significant ways. First, the phase II will assess the more therapeutic regimen of three (3) doses compared with two (2) in phase I. Second, this randomized trial compares ADXS11-001 alone with ADXS11-001 combined with platinum based chemotherapy. Combined immuno- and chemo-therapy regimens may be more effective than single agent regimens, and Advaxis has generated some anecdotal data in support of this idea in the phase I trial.
Patients will be randomly assigned to receive either three (3) administrations of ADXS11-001 (55 patients) or a single dose of the immunotherapy, followed by cisplatin treatment, followed by a three course regimen of ADXS11-001 (55 patients). Various clinical and immunologic measures will be taken and survival will be followed for the life of the patient.
About Advaxis Phase I Trial of ADXS11-001
ADXS11-001 is a live, attenuated Listeria vaccine that targets the human papilloma virus (HPV) oncoprotein E7. HPV is recognized as the cause of cervix cancer and E7 is one of the HPV proteins believed to be responsible. Doses of 1x109, 3.3x109 or 1x1010 cfu were administered to groups of five (5) women who had failed prior therapy including radiation and chemotherapy. In such cases, no therapy has been found to be effective and the median survival once disease progression resumes is typically six (6) months or less, depending upon the treatment given. One year survival for these patients historically is approximately 5%.
The phase I trial of ADXS11-001 was intended to assess safety. Like all phase I trials, it was not powered for efficacy; so, no conclusions can be made based upon the small number of patients treated. However, in this trial, the median survival was 347 days and the 1 year survival was 53%.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research - UK and the Department of Homeland Security. Advaxis' technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board.
Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
Fax: 732-545-1084
mir@advaxis.com
or
Diana Moore, 732-545-1590
Analyst
Fax: 732-545-1084
dmoore@advaxis.com
© 2010 Business Wire
ADXS11-001 With and Without Chemotherapy for the Treatment of Advanced Progressive Cervix Cancer in Women Who Have Failed Cytotoxic Therapy
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has begun dosing patients in its 110 patient clinical trial of ADXS11-001 for the treatment of cervix cancer in women for whom cytotoxic treatment has failed. This follows extensive review by the office of the Drugs Controller General of India, a blue ribbon commission of scientists convened to assess Advaxis clinical protocol, and a chemical and microbiological assessment of ADXS11-001 by the Indian Central Vaccine Research Laboratory at Kasuli. The initial patient is at the Dr. Kamakshi Memorial Hospital in Chennai.
The U.S. National Cancer Institute's Gynecologic Oncology Group has conducted 16 clinical trials in over 500 patients using various therapeutic regimens in this patient population and found the most effective regimen tested resulted in a median survival of approximately 6 months and a 1 year survival of 5%. By contrast, in a phase 1 study not designed to show efficacy, ADXS11-001 demonstrate a median survival of 347 days and a one year survival of 53%.
Because of the progressive and rapidly fatal nature of cervix cancer in women for whom cytotoxic treatment has failed, the design of this trial allows for a rapid appraisal of efficacy. Advaxis intends to report the effect of ADXS11-001 on survival versus these historical values in "real time", as the trial progresses, beginning in Summer, 2011.
About Advaxis Indian Phase II Trial of ADXS11-001
This trial differs from Advaxis phase I trial in this patient population in two significant ways. First, the phase II will assess the more therapeutic regimen of three (3) doses compared with two (2) in phase I. Second, this randomized trial compares ADXS11-001 alone with ADXS11-001 combined with platinum based chemotherapy. Combined immuno- and chemo-therapy regimens may be more effective than single agent regimens, and Advaxis has generated some anecdotal data in support of this idea in the phase I trial.
Patients will be randomly assigned to receive either three (3) administrations of ADXS11-001 (55 patients) or a single dose of the immunotherapy, followed by cisplatin treatment, followed by a three course regimen of ADXS11-001 (55 patients). Various clinical and immunologic measures will be taken and survival will be followed for the life of the patient.
About Advaxis Phase I Trial of ADXS11-001
ADXS11-001 is a live, attenuated Listeria vaccine that targets the human papilloma virus (HPV) oncoprotein E7. HPV is recognized as the cause of cervix cancer and E7 is one of the HPV proteins believed to be responsible. Doses of 1x109, 3.3x109 or 1x1010 cfu were administered to groups of five (5) women who had failed prior therapy including radiation and chemotherapy. In such cases, no therapy has been found to be effective and the median survival once disease progression resumes is typically six (6) months or less, depending upon the treatment given. One year survival for these patients historically is approximately 5%.
The phase I trial of ADXS11-001 was intended to assess safety. Like all phase I trials, it was not powered for efficacy; so, no conclusions can be made based upon the small number of patients treated. However, in this trial, the median survival was 347 days and the 1 year survival was 53%.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research - UK and the Department of Homeland Security. Advaxis' technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board.
Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis, Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
Fax: 732-545-1084
mir@advaxis.com
or
Diana Moore, 732-545-1590
Analyst
Fax: 732-545-1084
dmoore@advaxis.com
© 2010 Business Wire
The science team from Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, met with the Data Safety Monitoring Board (DSMB), an independent group of medical experts, yesterday and received approval to dose all remaining patients in the initial forty (40) patient leg of the 120-patient, cervical dysplasia clinical trial being conducted in the United States.
This meeting was a required step in the protocol agreed to with the U.S. Food and Drug Administration.
The protocol, agreed to by the FDA, required that an initial group of patients be treated and assessed by a DSMB prior to enrolling the full complement of patients in each forty (40) patient group.
“We are pleased with the pace of enrollment and the continued finding of safety in all Phase II participants,” commented Advaxis EVP of Science and Operations Dr. John Rothman. “Our lead construct, ADXS11-001, was well tolerated in all treated patients. The DSMB found no safety issues that warranted any change in the conduct of the trial.”
Overall, thirty-eight (38) patients have been dosed in two (2) trials. By year end, it is anticipated that there will be a database of more than 200 dosed patients.”
About the Data Safety Monitoring Board (DSMB)
It is the policy of the National Institutes of Health (NIH) that each Institute and Center (IC) should have a system for the appropriate oversight and monitoring of the conduct of clinical trials to ensure the safety of participants and the validity and integrity of the data for all NIH-supported or conducted clinical trials. The establishment of the data safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risk to the participants. The data and safety monitoring functions and oversight of such activities are distinct from the requirement for study review and approval by an Institutional Review Board (IRB).
This meeting was a required step in the protocol agreed to with the U.S. Food and Drug Administration.
The protocol, agreed to by the FDA, required that an initial group of patients be treated and assessed by a DSMB prior to enrolling the full complement of patients in each forty (40) patient group.
“We are pleased with the pace of enrollment and the continued finding of safety in all Phase II participants,” commented Advaxis EVP of Science and Operations Dr. John Rothman. “Our lead construct, ADXS11-001, was well tolerated in all treated patients. The DSMB found no safety issues that warranted any change in the conduct of the trial.”
Overall, thirty-eight (38) patients have been dosed in two (2) trials. By year end, it is anticipated that there will be a database of more than 200 dosed patients.”
About the Data Safety Monitoring Board (DSMB)
It is the policy of the National Institutes of Health (NIH) that each Institute and Center (IC) should have a system for the appropriate oversight and monitoring of the conduct of clinical trials to ensure the safety of participants and the validity and integrity of the data for all NIH-supported or conducted clinical trials. The establishment of the data safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risk to the participants. The data and safety monitoring functions and oversight of such activities are distinct from the requirement for study review and approval by an Institutional Review Board (IRB).
Antwort auf Beitrag Nr.: 40.864.510 von dottore am 14.01.11 17:15:06ständig gute News, ob Fortschritte in den klinischen Phasen, oder zur Sicherung der Finanzierung. Und doch sind wir 50 % unter dem Höchstkurs von 2010.
Bin gespannt, wann hier das Interesse her kommt. Jedenfalls derzeit eine Halteposition für mich, habe zum Höchstkurs mit 24 Cent auch keine Gewinne mitgenommen. Ich will 1 $, mindestens.
Bin gespannt, wann hier das Interesse her kommt. Jedenfalls derzeit eine Halteposition für mich, habe zum Höchstkurs mit 24 Cent auch keine Gewinne mitgenommen. Ich will 1 $, mindestens.
es ist sehr edel wenn Anleger treu bleiben, aber den 1$ wirst du erst nächstes Jahr sehen. Wenn du Glück hast geht es es auf 0,30 $ im laufe dieses Jahres.
Aber das ist natürlich nur meine Meinung. Also sicher nicht so wichtig.
Aber das ist natürlich nur meine Meinung. Also sicher nicht so wichtig.
Dank an MOD
wenn der 1 $ nächstes Jahr kommt, dann wäre es immer noch eine ver8-fachung in 1 Jahr. Dafür kann man auch mal treu sein ;-)
Advaxis Science & Operations Officer Moderates Live Vaccine Panel at Cancer Drug Research Conference
Published: January 28, 2011
Paradise Point Resort Hotel, San Diego, CA | January 27 -28, 2011
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 28, 2011-- Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, “Live Cancer Vaccines.”
Topics addressed by the panel included:
The novelty of live vaccines which offer immunologic therapeutic alternatives never available previously; with new mechanisms of action and unprecedented efficacy in certain indications.
The safety of live vaccines is significantly greater than chemotherapy or radiotherapy, and is much better tolerated by patients.
Not only do these agents possess immunologic efficacy, but they appear to work well with chemotherapy and radiation, thus offering additional alternatives not previously possible.
Live vaccines are a developing area of science that has the potential to change the way in which drugs are delivered to patients. Unlike conventional therapy where biologically active chemicals are administered, live vaccines infect the patient’s cells to be treated and make the active drugs from the inside of these cells, where they are used.
Some noteworthy publicly-traded healthcare companies and governmental institutions in attendance included: Pfizer Oncology (NYSE: PFE), Genentech Roche (OTCQX: RHHBY), the National Cancer Institute (NCI), and the Tumor Immunology and Biology, Medical Oncology Branch of National Institutes of Health (NIH).
About the 8th Annual Cancer Drugs Research and Development Conference
The 8th Annual Cancer Drugs Research and Development Conference on January 27-28, 2011 in San Diego, California, US will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide you with an update on cancer drugs currently in development through clinical trials., A look at live cancer vaccines, novel compounds and antibody drug conjugates will prime delegates and guests with the future direction of cancer drugs with key topics to be discussed by leading experts.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.
Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. ,The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc.
Advaxis, Incorporated
Conrad F. Mir, 732-545-1590 (Office)
Executive Director
732-545-1084 (FAX)
mir@advaxis.com
or
Advaxis, Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
Published: January 28, 2011
Paradise Point Resort Hotel, San Diego, CA | January 27 -28, 2011
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Jan. 28, 2011-- Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, “Live Cancer Vaccines.”
Topics addressed by the panel included:
The novelty of live vaccines which offer immunologic therapeutic alternatives never available previously; with new mechanisms of action and unprecedented efficacy in certain indications.
The safety of live vaccines is significantly greater than chemotherapy or radiotherapy, and is much better tolerated by patients.
Not only do these agents possess immunologic efficacy, but they appear to work well with chemotherapy and radiation, thus offering additional alternatives not previously possible.
Live vaccines are a developing area of science that has the potential to change the way in which drugs are delivered to patients. Unlike conventional therapy where biologically active chemicals are administered, live vaccines infect the patient’s cells to be treated and make the active drugs from the inside of these cells, where they are used.
Some noteworthy publicly-traded healthcare companies and governmental institutions in attendance included: Pfizer Oncology (NYSE: PFE), Genentech Roche (OTCQX: RHHBY), the National Cancer Institute (NCI), and the Tumor Immunology and Biology, Medical Oncology Branch of National Institutes of Health (NIH).
About the 8th Annual Cancer Drugs Research and Development Conference
The 8th Annual Cancer Drugs Research and Development Conference on January 27-28, 2011 in San Diego, California, US will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide you with an update on cancer drugs currently in development through clinical trials., A look at live cancer vaccines, novel compounds and antibody drug conjugates will prime delegates and guests with the future direction of cancer drugs with key topics to be discussed by leading experts.
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.
Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. ,The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Source: Advaxis, Inc.
Advaxis, Incorporated
Conrad F. Mir, 732-545-1590 (Office)
Executive Director
732-545-1084 (FAX)
mir@advaxis.com
or
Advaxis, Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
Antwort auf Beitrag Nr.: 40.949.317 von jacci am 30.01.11 08:19:5415.02.2011 20:37
Advaxis Included in the Mentor Capital Cancer Immunotherapy Index
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index (the "Index"), an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector.
Mentor Capital states that the Index is calculated and presented based upon a theoretical $1,000 investment in each CI Index company starting at the time of Index formation on July 10, 2009 with mathematical adjustments for the addition of new companies.
On Advaxis' inclusion into the Index, Mentor Capital Chairman/CEO and Founder Chester Billingsley said, "We have watched Advaxis Incorporated with positive anticipation over the last eighteen months as it increased its focus toward cancer therapy so that we could bring them into our Cancer Immunotherapy Index. As a scientist, I'm excited about including them as a strong new addition. Dr. Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens. As a natural result, Advaxis has, and we believe will continue to add, multiple drugs in clinic and collaborations with governments and leading institutions. The inherent ability to deliver against multiple cancer lines, the strong reported tumor defeating response, and the unique technology are similar to the advantages that delivered such a strong portfolio return for Mentor Capital from Dendreon (Nasdaq: DNDN) and Immuno Cellular Therapeutics (OTCBB: IMUC)."
The annualized Index return, since inception in 2009 has been 48%.
"This inclusion into the Mentor Capital Cancer Immunotherapy Index is a significant step forward for the Company," said Chairman/CEO Thomas A. Moore. "We welcome the added visibility this will bring to our strong science and broad based clinical programs."
About The Mentor Capital Immunotherapy Index
The Cancer Immunotherapy Index is an index of initially ten (10) companies known by Mentor Capital and judged to be substantially and predominantly involved in the cancer immunotherapy sector. A company that is not yet large enough or a company that is already larger but involved in mostly other things will not be included in the CI Index. Companies that grow, become more specialized in cancer immunotherapy or become better known to Mentor Capital may be added to the Index over time. For more information about the Index, please visit: http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html…
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by The University of Pennsylvania. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research - UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
mir@advaxis.com
or
Advaxis Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
dmoore@advaxis.com
© 2011 Business Wire
Advaxis Included in the Mentor Capital Cancer Immunotherapy Index
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index (the "Index"), an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector.
Mentor Capital states that the Index is calculated and presented based upon a theoretical $1,000 investment in each CI Index company starting at the time of Index formation on July 10, 2009 with mathematical adjustments for the addition of new companies.
On Advaxis' inclusion into the Index, Mentor Capital Chairman/CEO and Founder Chester Billingsley said, "We have watched Advaxis Incorporated with positive anticipation over the last eighteen months as it increased its focus toward cancer therapy so that we could bring them into our Cancer Immunotherapy Index. As a scientist, I'm excited about including them as a strong new addition. Dr. Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens. As a natural result, Advaxis has, and we believe will continue to add, multiple drugs in clinic and collaborations with governments and leading institutions. The inherent ability to deliver against multiple cancer lines, the strong reported tumor defeating response, and the unique technology are similar to the advantages that delivered such a strong portfolio return for Mentor Capital from Dendreon (Nasdaq: DNDN) and Immuno Cellular Therapeutics (OTCBB: IMUC)."
The annualized Index return, since inception in 2009 has been 48%.
"This inclusion into the Mentor Capital Cancer Immunotherapy Index is a significant step forward for the Company," said Chairman/CEO Thomas A. Moore. "We welcome the added visibility this will bring to our strong science and broad based clinical programs."
About The Mentor Capital Immunotherapy Index
The Cancer Immunotherapy Index is an index of initially ten (10) companies known by Mentor Capital and judged to be substantially and predominantly involved in the cancer immunotherapy sector. A company that is not yet large enough or a company that is already larger but involved in mostly other things will not be included in the CI Index. Companies that grow, become more specialized in cancer immunotherapy or become better known to Mentor Capital may be added to the Index over time. For more information about the Index, please visit: http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html…
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by The University of Pennsylvania. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research - UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company's portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad F. Mir, 732-545-1590
Executive Director
732-545-1084 (FAX)
mir@advaxis.com
or
Advaxis Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
dmoore@advaxis.com
© 2011 Business Wire
so langsam steigt der Kurs wieder. Dabei wird die 38Tagelinie von unten an die 200Tagelinie herangezogen. Eigentlich ein gutes Zeichen für einen Ausbruch nach oben. Es stehen wieder NEWS an. Vielleicht passt beides Zeitlich zusammen. Dann gibt es auf jeden Fall einen Hype, vielleicht schon in den nächsten 2 Wochen.
Weiß hier jemand, wann die FDA-Zulassung erwartet wird? Und wo man da (kostenlos) nachschauen kann?
Weiß hier jemand, wann die FDA-Zulassung erwartet wird? Und wo man da (kostenlos) nachschauen kann?
Antwort auf Beitrag Nr.: 41.069.041 von dottore am 18.02.11 20:01:06Auszug aus dem Yahoo-Board
Re: Reporting of India Results Realistic??? 10-Feb-11 03:50 pm I've been doing a lot of thinking about this thread.
Mr. Moore stated that reporting will begin when the median survival hits 6 months. We will then get updates on median survival every month thereafter.
Given all the other info we have regarding currently dosed patients and enrollment rate... and Mr. Moore's statement that reporting will hopefully begin late august/early September.... one can only assume that this reporting will take place before all 110 patients are dosed.
That is fine with me. But then as new patients are added (around 12 per month according to last call) the median survival might stay the same or even decrease in the following months.... however this wouldn't necessarily mean the study is going poorly.... it would just be a reflection of new patients added to the study group. It seems to me that this could be very confusing to investors looking at such updates. However if the median survival continues to increase despite new patient enrollment... that would mean that Advaxis results are destroying the previous historical median survival results.
I consider the Advaxis management team to be very intelligent so I am going to look at this as a huge positive. They obviously think their results are going to be so disruptive, that new patient enrollment will have no effect on their monthly updates.
There is just no other explanation for why management would take that risk. No one is holding a gun to their heads saying they must report results by summer's end. It would seem much safer to just wait until everyone is dosed and then report increasing median survival every month until half the patients have died without risking a possible scenario whereby they report a median survival of 6 months and then next month it's only 5 and then the month after it goes back to 6.
Is my logic off here? Am I thinking in circles? Will I ever stop rambling? ....
Re: Reporting of India Results Realistic??? 10-Feb-11 03:50 pm I've been doing a lot of thinking about this thread.
Mr. Moore stated that reporting will begin when the median survival hits 6 months. We will then get updates on median survival every month thereafter.
Given all the other info we have regarding currently dosed patients and enrollment rate... and Mr. Moore's statement that reporting will hopefully begin late august/early September.... one can only assume that this reporting will take place before all 110 patients are dosed.
That is fine with me. But then as new patients are added (around 12 per month according to last call) the median survival might stay the same or even decrease in the following months.... however this wouldn't necessarily mean the study is going poorly.... it would just be a reflection of new patients added to the study group. It seems to me that this could be very confusing to investors looking at such updates. However if the median survival continues to increase despite new patient enrollment... that would mean that Advaxis results are destroying the previous historical median survival results.
I consider the Advaxis management team to be very intelligent so I am going to look at this as a huge positive. They obviously think their results are going to be so disruptive, that new patient enrollment will have no effect on their monthly updates.
There is just no other explanation for why management would take that risk. No one is holding a gun to their heads saying they must report results by summer's end. It would seem much safer to just wait until everyone is dosed and then report increasing median survival every month until half the patients have died without risking a possible scenario whereby they report a median survival of 6 months and then next month it's only 5 and then the month after it goes back to 6.
Is my logic off here? Am I thinking in circles? Will I ever stop rambling? ....
Antwort auf Beitrag Nr.: 41.074.096 von jacci am 20.02.11 18:35:05http://www.faqs.org/sec-filings/110225/Advaxis-Inc_10-K.A/" target="_blank" rel="nofollow ugc noopener">http://www.faqs.org/sec-filings/110225/Advaxis-Inc_10-K.A/
Antwort auf Beitrag Nr.: 41.111.940 von jacci am 26.02.11 18:22:54http://www.onemedplace.com/database/list/cid/13343/
Antwort auf Beitrag Nr.: 41.112.706 von jacci am 27.02.11 09:12:31http://biotechstocktrader.com/advaxis-otcbb-adxs-pipeline-co…
Antwort auf Beitrag Nr.: 41.174.819 von jacci am 10.03.11 06:45:30Advaxis Included in the Mentor Capital Cancer Immunotherapy Index
Companies:ADVAXIS INC Related Quotes
Symbol Price Change
ADXS.OB 0.14 0.00
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index (the “Index”), an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector.
Mentor Capital states that the Index is calculated and presented based upon a theoretical $1,000 investment in each CI Index company starting at the time of Index formation on July 10, 2009 with mathematical adjustments for the addition of new companies.
On Advaxis’ inclusion into the Index, Mentor Capital Chairman/CEO and Founder Chester Billingsley said, “We have watched Advaxis Incorporated with positive anticipation over the last eighteen months as it increased its focus toward cancer therapy so that we could bring them into our Cancer Immunotherapy Index. As a scientist, I’m excited about including them as a strong new addition. Dr. Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens. As a natural result, Advaxis has, and we believe will continue to add, multiple drugs in clinic and collaborations with governments and leading institutions. The inherent ability to deliver against multiple cancer lines, the strong reported tumor defeating response, and the unique technology are similar to the advantages that delivered such a strong portfolio return for Mentor Capital from Dendreon (Nasdaq
NDN - News) and Immuno Cellular Therapeutics (OTCBB: IMUC).”
The annualized Index return, since inception in 2009 has been 48%.
“This inclusion into the Mentor Capital Cancer Immunotherapy Index is a significant step forward for the Company,” said Chairman/CEO Thomas A. Moore. “We welcome the added visibility this will bring to our strong science and broad based clinical programs.”
About The Mentor Capital Immunotherapy Index
The Cancer Immunotherapy Index is an index of initially ten (10) companies known by Mentor Capital and judged to be substantially and predominantly involved in the cancer immunotherapy sector. A company that is not yet large enough or a company that is already larger but involved in mostly other things will not be included in the CI Index. Companies that grow, become more specialized in cancer immunotherapy or become better known to Mentor Capital may be added to the Index over time. For more information about the Index, please visit: http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html…
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by The University of Pennsylvania. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contact:
Advaxis IncorporatedConrad F. Mir, 732-545-1590Executive Director732-545-1084 (FAX)mir@advaxis.comorAdvaxis IncorporatedDiana Moore, 732-545-1590Analyst732-545-1084 (FAX)dmoore@advaxis.com
Companies:ADVAXIS INC Related Quotes
Symbol Price Change
ADXS.OB 0.14 0.00
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been included in the Mentor Capital Cancer Immunotherapy Index (the “Index”), an index of companies judged noteworthy by Mentor Capital that are predominantly involved in the cancer immunotherapy sector.
Mentor Capital states that the Index is calculated and presented based upon a theoretical $1,000 investment in each CI Index company starting at the time of Index formation on July 10, 2009 with mathematical adjustments for the addition of new companies.
On Advaxis’ inclusion into the Index, Mentor Capital Chairman/CEO and Founder Chester Billingsley said, “We have watched Advaxis Incorporated with positive anticipation over the last eighteen months as it increased its focus toward cancer therapy so that we could bring them into our Cancer Immunotherapy Index. As a scientist, I’m excited about including them as a strong new addition. Dr. Yvonne Paterson of the University of Pennsylvania has developed a promising immunotherapeutic platform and technology that lends itself to delivering immune triggers against a number of cancer antigens. As a natural result, Advaxis has, and we believe will continue to add, multiple drugs in clinic and collaborations with governments and leading institutions. The inherent ability to deliver against multiple cancer lines, the strong reported tumor defeating response, and the unique technology are similar to the advantages that delivered such a strong portfolio return for Mentor Capital from Dendreon (Nasdaq
NDN - News) and Immuno Cellular Therapeutics (OTCBB: IMUC).” The annualized Index return, since inception in 2009 has been 48%.
“This inclusion into the Mentor Capital Cancer Immunotherapy Index is a significant step forward for the Company,” said Chairman/CEO Thomas A. Moore. “We welcome the added visibility this will bring to our strong science and broad based clinical programs.”
About The Mentor Capital Immunotherapy Index
The Cancer Immunotherapy Index is an index of initially ten (10) companies known by Mentor Capital and judged to be substantially and predominantly involved in the cancer immunotherapy sector. A company that is not yet large enough or a company that is already larger but involved in mostly other things will not be included in the CI Index. Companies that grow, become more specialized in cancer immunotherapy or become better known to Mentor Capital may be added to the Index over time. For more information about the Index, please visit: http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html…
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live but attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Our platform technology was developed by The University of Pennsylvania. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh, Cancer Research – UK, the University of British Columbia and the Department of Homeland Security. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contact:
Advaxis IncorporatedConrad F. Mir, 732-545-1590Executive Director732-545-1084 (FAX)mir@advaxis.comorAdvaxis IncorporatedDiana Moore, 732-545-1590Analyst732-545-1084 (FAX)dmoore@advaxis.com
Antwort auf Beitrag Nr.: 41.308.789 von jacci am 02.04.11 20:11:19hier der Link,
hoffe es funktioniert...
http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html
hoffe es funktioniert...
http://www.mentorcapital.com/Cancer_Immunotherapy_Index.html
Antwort auf Beitrag Nr.: 41.309.258 von jacci am 03.04.11 08:37:56http://www.zacks.com/stock/news/51041/Advaxis+Inc.%3A+Initia…
endlich zieht der Kurs an! Wenn man bedenkt, dass ich mit dem Wert den Ausstieg bei 24 Cent verpennt habe und jetzt gerade mal wieder bei null bin. Ist schon heftig. Aber 1 $ soll erklommen werden, nicht nur 50 Cent wie bei zacks genannt. Ich bin schließlich schon länger drin 
Antwort auf Beitrag Nr.: 41.362.718 von dottore am 13.04.11 17:42:47Cancer Immunol Immunother. 2011 Mar 23. [Epub ahead of print]
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.
Department of Microbiology, University of Pennsylvania, 323 Johnson Pavilion, Philadelphia, PA, 19104, USA.
Abstract
The FDA approval of bevacizumab (Avastin(®), Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identified. One promising target present specifically on tumor vasculature is endoglin (CD105), a member of the TGF-β receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic efficacy against primary and metastatic breast cancer.PMID: 21431419 [PubMed - as supplied by publisher]
LinkOut - more resources
ADXS wird schon mit DNDN verglichen .......
Da käme ja was auf uns zu.....
IMHO Jacci
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105.
Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M, Paterson Y.
Department of Microbiology, University of Pennsylvania, 323 Johnson Pavilion, Philadelphia, PA, 19104, USA.
Abstract
The FDA approval of bevacizumab (Avastin(®), Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for anti-angiogenesis tumor therapy, additional targets involved in tumor neovascularization have been identified. One promising target present specifically on tumor vasculature is endoglin (CD105), a member of the TGF-β receptor complex expressed on vascular endothelium and believed to play a role in angiogenesis. Monoclonal antibody therapy and preventive vaccination against CD105 has met with some success in controlling tumor growth. This report describes the in vivo proof-of-concept studies for two novel therapeutic vaccines, Lm-LLO-CD105A and Lm-LLO-CD105B, directed against CD105 as a strategy to target neovascularization of established tumors. Listeria-based vaccines directed against CD105 lead to therapeutic responses against primary and metastatic tumors in the 4T1-Luc and NT-2 mouse models of breast cancer. In a mouse model for autochthonous Her-2/neu-driven breast cancer, Lm-LLO-CD105A vaccination prevented tumor incidence in 20% of mice by week 58 after birth while all control mice developed tumors by week 40. In comparison with previous Listeria-based vaccines targeting tumor vasculature, Lm-LLO-CD105A and Lm-LLO-CD105B demonstrated equivalent or superior efficacy against two transplantable mouse models of breast cancer. Support is provided for epitope spreading to endogenous tumor antigens and reduction in tumor vascularity after vaccination with Listeria-based CD105 vaccines. Reported here, these CD105 therapeutic vaccines are highly effective in stimulating anti-angiogenesis and anti-tumor immune responses leading to therapeutic efficacy against primary and metastatic breast cancer.PMID: 21431419 [PubMed - as supplied by publisher]
LinkOut - more resources
ADXS wird schon mit DNDN verglichen .......
Da käme ja was auf uns zu.....
IMHO Jacci
ADXS wird schon mit DNDN verglichen .......
Da käme ja was auf uns zu.....
das müssen wir gleich allen weiter erzählen
nicht dass die uns nachher vorhalten, wir hätten nicht rechtzeitig bescheid gesagt
Da käme ja was auf uns zu.....
das müssen wir gleich allen weiter erzählen
nicht dass die uns nachher vorhalten, wir hätten nicht rechtzeitig bescheid gesagt
Antwort auf Beitrag Nr.: 41.363.918 von dottore am 13.04.11 21:06:52hier ein älteres Video mit dem CEO Rothman
Thema: Cervial Cancer Vaccine....
Thread: Postings wieder in voller Laenge hergestellt!!!!!!!!
Thema: Cervial Cancer Vaccine....
Thread: Postings wieder in voller Laenge hergestellt!!!!!!!!
Antwort auf Beitrag Nr.: 41.367.953 von jacci am 14.04.11 15:11:24http://www.youtube.com/watch?v=THmr3YxSGts&feature=related
so ist der Link natürlich...
so ist der Link natürlich...
Meldung von heute
Advaxis Reaches Collaboration With Wistar Institute
Advaxis Reaches Collaboration With Wistar Institute
Antwort auf Beitrag Nr.: 41.368.408 von dottore am 14.04.11 16:07:15Thread: Kein Titel für Thread 164976997901
Antwort auf Beitrag Nr.: 41.369.417 von jacci am 14.04.11 18:13:17http://www.zacks.com/stock/news/51343/Advaxis%3A+Collaborati…
Antwort auf Beitrag Nr.: 41.380.609 von jacci am 17.04.11 20:20:31ADXS11-001 Well-Tolerated in 72 Patients, to Date
Advaxis EVP of Science and Operations Updated Clinical Trial Safety Findings at Target Meeting Webinar
Press Release Source: Advaxis Incorporated On Monday April 18, 2011, 1:12 pm EDT
PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. John Rothman, EVP of Science and Operations at Advaxis, Inc., (OTCBB:ADXS.ob - News), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, gave the lead presentation entitled, “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar held April 16, 2011 entitled “Immunotherapy: a promising way for cancer treatment.”
In his presentation, he reported:
a. Advaxis has treated 72 patients with 180 doses of live attenuated Listeria safely, to-date
b. Drug-related side effects have been infrequent and are typically mild to moderate when they occur
c. When side effects have occurred, they have been treated symptomatically and have not required antibiotics – indicating that the side effects are not related to the onset of Listerial disease but result from strong innate immune stimulation which causes a flu-like syndrome of fever and chills and occasionally nausea.
Of note, Dr. Rothman cited how unusual Listerial disease is
Advaxis EVP of Science and Operations Updated Clinical Trial Safety Findings at Target Meeting Webinar
Press Release Source: Advaxis Incorporated On Monday April 18, 2011, 1:12 pm EDT
PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. John Rothman, EVP of Science and Operations at Advaxis, Inc., (OTCBB:ADXS.ob - News), the live, attenuated Listeria monocytogenes (Listeria) vaccine company, gave the lead presentation entitled, “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar held April 16, 2011 entitled “Immunotherapy: a promising way for cancer treatment.”
In his presentation, he reported:
a. Advaxis has treated 72 patients with 180 doses of live attenuated Listeria safely, to-date
b. Drug-related side effects have been infrequent and are typically mild to moderate when they occur
c. When side effects have occurred, they have been treated symptomatically and have not required antibiotics – indicating that the side effects are not related to the onset of Listerial disease but result from strong innate immune stimulation which causes a flu-like syndrome of fever and chills and occasionally nausea.
Of note, Dr. Rothman cited how unusual Listerial disease is
Antwort auf Beitrag Nr.: 41.386.752 von jacci am 19.04.11 07:00:45http://stockcharts.com/h-sc/ui
schaut gut aus ...................
schaut gut aus ...................
Zitat von jacci: http://stockcharts.com/h-sc/ui
schaut gut aus ...................
natürlich adxs eingeben
Antwort auf Beitrag Nr.: 41.404.399 von jacci am 22.04.11 10:13:10http://seekingalpha.com/article/264697-
interessant....
interessant....
Zitat von jacci: http://seekingalpha.com/article/264697-
interessant....
und noch was als Osterlektüre
http://www.themarketfinancial.com/a-new-star-in-cancer-thera…
Antwort auf Beitrag Nr.: 41.406.278 von jacci am 23.04.11 16:13:55http://www.sciencenews.org/vi...
interessanter Artikel, ADXS wird in der Mitte des Artikels erwähnt...
" Trove of Trials "
Bin gespannt heute auf Handelsbeginn (in den USA hat heute die Börse geöffnet)
interessanter Artikel, ADXS wird in der Mitte des Artikels erwähnt...
" Trove of Trials "
Bin gespannt heute auf Handelsbeginn (in den USA hat heute die Börse geöffnet)
Zitat von jacci: http://www.sciencenews.org/vi...
interessanter Artikel, ADXS wird in der Mitte des Artikels erwähnt...
" Trove of Trials "
Bin gespannt heute auf Handelsbeginn (in den USA hat heute die Börse geöffnet)
http://www.sciencenews.org/view/feature/id/73286/title/Crush…
jetzt müßte der Link funktionieren....
die 0,24 $ sind einfach nicht zu knacken. Der Kurs stürzt noch mal so richtig ab.
Ich bin zwar gut im Plus, aber nachdem ich die Aktie schon so lange halte, will ich mehr! Viel mehr! Sehr viel mehr! Ein vielfaches vom heutigen Kurs!
Ich bin zwar gut im Plus, aber nachdem ich die Aktie schon so lange halte, will ich mehr! Viel mehr! Sehr viel mehr! Ein vielfaches vom heutigen Kurs!
Antwort auf Beitrag Nr.: 41.465.973 von dottore am 06.05.11 15:52:20hier ein Interview mit Thomas Moore, CEO von Advaxis von 2010
http://www.youtube.com/watch?v=Z0Ao1P2vQl8
derzeit ein wenig Konsolitierung, aber wird schon werden mit unserem Schmuckstück...
wie habt Ihr eingekauft ?
in Stuttgart gingen diese Woche etwas überteuerte Stücke über den Tresen....
unsere Zeit wird schon noch kommen....
http://www.youtube.com/watch?v=Z0Ao1P2vQl8
derzeit ein wenig Konsolitierung, aber wird schon werden mit unserem Schmuckstück...
wie habt Ihr eingekauft ?
in Stuttgart gingen diese Woche etwas überteuerte Stücke über den Tresen....
unsere Zeit wird schon noch kommen....
Antwort auf Beitrag Nr.: 41.469.481 von jacci am 07.05.11 20:03:15http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=2029&Enc…
hier der Indien-Trial, Ergebnisse werden im Sommer erwartet....
hoffen wir mal auf gute Nachrichten...
hier der Indien-Trial, Ergebnisse werden im Sommer erwartet....
hoffen wir mal auf gute Nachrichten...
über 24 Cent will die Aktie einfach nicht steigen! Wir sind ja schon iweder 30% drunter. Wenn ich schon nicht für 24 verkaufe, dann sollte ich vielleicht nachkaufen ...
Antwort auf Beitrag Nr.: 41.494.030 von dottore am 12.05.11 19:20:48Investor Präsentation 2011
http://www.advaxis.com/assets/uploads/documents/advaxis_gene…
Zeit zum Einsammeln............
IMOH
Jacci
http://www.advaxis.com/assets/uploads/documents/advaxis_gene…
Zeit zum Einsammeln............
IMOH
Jacci
jemand gönnte sich am Freitag folgendes folgende Shares:
19:33:03 0.15 VA 194.000 29.100
sagte ja, Einsammeln zu diesen Preisen ist angesagt...........
IMHO
jacci
19:33:03 0.15 VA 194.000 29.100
sagte ja, Einsammeln zu diesen Preisen ist angesagt...........
IMHO
jacci
Antwort auf Beitrag Nr.: 41.636.848 von jacci am 11.06.11 18:29:26http://www.finanznachrichten.de/nachrichten-2011-06/20670021…
es wird langsam spannend....
es wird langsam spannend....
Price Size Exch Time
$0.1750 180,000 OBB 16:02:28 $0.1730 5,700 OBB 15:59:10
$0.1700 2,000 OBB 15:59:06
$0.1730 1,500 OBB 15:57:22
$0.1700 390 OBB 15:37:42
$0.1700 2,000 OBB 15:36:04
$0.1730 250 OBB 15:33:19
$0.1730 22,000 OBB 15:16:11
$0.1700 3,900 OBB 14:58:03
$0.1700 1,100 OBB 14:58:01
$0.1750 1,000 OBB 14:56:13
$0.1700 70,000 OBB 14:42:01
$0.1750 20,000 OBB 14:41:56
$0.1750 5,000 OBB 14:39:28
$0.1750 2,000 OBB 14:35:40
$0.1750 5,000 OBB 14:35:02
$0.1750 100 OBB 14:24:04
$0.1750 1,000 OBB 14:12:19
$0.1750 2,250 OBB 14:09:15
$0.1750 40,000 OBB 14:06:37
$0.1700 5,988 OBB 14:06:37
$0.1705 5,000 OBB 14:06:33
$0.1705 5,000 OBB 14:05:35
$0.1710 30,000 OBB 13:54:48
$0.1705 23,000 OBB 13:54:17
$0.1750 6,000 OBB 13:53:53
$0.1780 4,999 OBB 13:47:11
$0.1780 2,500 OBB 13:33:37
$0.1780 3,700 OBB 13:03:48
$0.1800 3,610 OBB 13:03:27
schöner Kauf nach 16:00 Uhr..............
wird schon was......
IHO jacci
$0.1750 180,000 OBB 16:02:28 $0.1730 5,700 OBB 15:59:10
$0.1700 2,000 OBB 15:59:06
$0.1730 1,500 OBB 15:57:22
$0.1700 390 OBB 15:37:42
$0.1700 2,000 OBB 15:36:04
$0.1730 250 OBB 15:33:19
$0.1730 22,000 OBB 15:16:11
$0.1700 3,900 OBB 14:58:03
$0.1700 1,100 OBB 14:58:01
$0.1750 1,000 OBB 14:56:13
$0.1700 70,000 OBB 14:42:01
$0.1750 20,000 OBB 14:41:56
$0.1750 5,000 OBB 14:39:28
$0.1750 2,000 OBB 14:35:40
$0.1750 5,000 OBB 14:35:02
$0.1750 100 OBB 14:24:04
$0.1750 1,000 OBB 14:12:19
$0.1750 2,250 OBB 14:09:15
$0.1750 40,000 OBB 14:06:37
$0.1700 5,988 OBB 14:06:37
$0.1705 5,000 OBB 14:06:33
$0.1705 5,000 OBB 14:05:35
$0.1710 30,000 OBB 13:54:48
$0.1705 23,000 OBB 13:54:17
$0.1750 6,000 OBB 13:53:53
$0.1780 4,999 OBB 13:47:11
$0.1780 2,500 OBB 13:33:37
$0.1780 3,700 OBB 13:03:48
$0.1800 3,610 OBB 13:03:27
schöner Kauf nach 16:00 Uhr..............
wird schon was......
IHO jacci
UPenn Initiates Canine Osteosarcoma Study with Advaxis HER2
ADXS.OB 0.20 +0.01
Press Release Source: Advaxis Incorporated On Thursday July 7, 2011, 2:45 pm EDT
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (OTCBB:ADXS.ob - News), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.
Canine Osteosarcoma is a cancer of long (leg) bones that is a leading killer of large dogs over the age of 10 years. Standard treatment is amputation immediately after diagnosis, followed by chemotherapy. Invariably, however, the cancer metastasizes to the lungs. With chemotherapy, dogs survive about 18 months compared to 6-12 months, without treatment. The HER2 antigen is believed to be present in up to 50% of osteosarcoma. ADXS-HER2 creates an immune attack on cells expressing this antigen and has been developed to treat human breast cancer. The Company plans to file an IND later this year for this indication.
In 2010, Advaxis contracted with the University of Pennsylvania School of Veterinary Medicine to conduct a canine clinical program to determine the safety and efficacy of ADXS-HER2 in osteosarcoma. Positive results may lead to research in humans, as well.
“There is an especially high unmet need for safe, effective and reasonably priced cancer therapy in the companion animal market,” commented Thomas A Moore, Chairman and CEO of Advaxis, Inc. “This early study gets us started.”
About the Canine Osteosarcoma Trial
The study will be under the direction of Dr. Nicola Mason, an assistant professor at the University of Pennsylvania School of Veterinary Medicine. Only dogs with a histological diagnosis of osteosarcoma and evidence of expression of HER2/neu by malignant cells will be eligible for enrollment.
All dogs will receive 4 weeks of carboplatin therapy. Four weeks after the last carboplatin dose, dogs will receive ADXS-HER2 once every three weeks for a total of 3 doses. Group 1 (3 dogs) will receive 1x108 CFU per dose, Group 2 (3 dogs) will each receive 5x108 CFU per dose and Group 3 (3 dogs) will receive 1x109 CFU per dose. Additional dogs may be added to a Group to gather more data should if a potentially dose limiting toxicities, be observed. Therefore 9-18 dogs may be treated in the initial study.
About the University of Pennsylvania School of Veterinary Medicine
Penn's School of Veterinary Medicine is one of the world's premier veterinary schools. Founded in 1884, the School was built on the concept of Many Species, One Medicine™. The birthplace of veterinary specialties, the School serves a distinctly diverse array of animal patients, from pets to horses to farm animals at our two campuses. In Philadelphia, on Penn's campus, are the Matthew J. Ryan Veterinary Hospital for companion animals, as well as classrooms, laboratories and the School's administrative offices. The large-animal facility, New Bolton Center, in Kennett Square, Pa., encompasses hospital facilities for the care of horses and food animals as well as diagnostic laboratories serving the agriculture industry. The School has successfully integrated scholarship and scientific discovery with all aspects of veterinary medical education.
ADXS.OB 0.20 +0.01
Press Release Source: Advaxis Incorporated On Thursday July 7, 2011, 2:45 pm EDT
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (OTCBB:ADXS.ob - News), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announces that the first dog has entered a dose-ranging in canine osteosarcoma at the University of Pennsylvania School of Veterinary Medicine.
Canine Osteosarcoma is a cancer of long (leg) bones that is a leading killer of large dogs over the age of 10 years. Standard treatment is amputation immediately after diagnosis, followed by chemotherapy. Invariably, however, the cancer metastasizes to the lungs. With chemotherapy, dogs survive about 18 months compared to 6-12 months, without treatment. The HER2 antigen is believed to be present in up to 50% of osteosarcoma. ADXS-HER2 creates an immune attack on cells expressing this antigen and has been developed to treat human breast cancer. The Company plans to file an IND later this year for this indication.
In 2010, Advaxis contracted with the University of Pennsylvania School of Veterinary Medicine to conduct a canine clinical program to determine the safety and efficacy of ADXS-HER2 in osteosarcoma. Positive results may lead to research in humans, as well.
“There is an especially high unmet need for safe, effective and reasonably priced cancer therapy in the companion animal market,” commented Thomas A Moore, Chairman and CEO of Advaxis, Inc. “This early study gets us started.”
About the Canine Osteosarcoma Trial
The study will be under the direction of Dr. Nicola Mason, an assistant professor at the University of Pennsylvania School of Veterinary Medicine. Only dogs with a histological diagnosis of osteosarcoma and evidence of expression of HER2/neu by malignant cells will be eligible for enrollment.
All dogs will receive 4 weeks of carboplatin therapy. Four weeks after the last carboplatin dose, dogs will receive ADXS-HER2 once every three weeks for a total of 3 doses. Group 1 (3 dogs) will receive 1x108 CFU per dose, Group 2 (3 dogs) will each receive 5x108 CFU per dose and Group 3 (3 dogs) will receive 1x109 CFU per dose. Additional dogs may be added to a Group to gather more data should if a potentially dose limiting toxicities, be observed. Therefore 9-18 dogs may be treated in the initial study.
About the University of Pennsylvania School of Veterinary Medicine
Penn's School of Veterinary Medicine is one of the world's premier veterinary schools. Founded in 1884, the School was built on the concept of Many Species, One Medicine™. The birthplace of veterinary specialties, the School serves a distinctly diverse array of animal patients, from pets to horses to farm animals at our two campuses. In Philadelphia, on Penn's campus, are the Matthew J. Ryan Veterinary Hospital for companion animals, as well as classrooms, laboratories and the School's administrative offices. The large-animal facility, New Bolton Center, in Kennett Square, Pa., encompasses hospital facilities for the care of horses and food animals as well as diagnostic laboratories serving the agriculture industry. The School has successfully integrated scholarship and scientific discovery with all aspects of veterinary medical education.
Antwort auf Beitrag Nr.: 41.759.258 von jacci am 08.07.11 06:30:18http://snnwire.com/media/video_558
Antwort auf Beitrag Nr.: 41.779.599 von jacci am 13.07.11 06:50:54http://www.terrapinn.com/2011/world-vaccine-congress-lyon/SP…
Antwort auf Beitrag Nr.: 41.791.206 von jacci am 14.07.11 20:58:43http://finance.yahoo.com/news/Dr-Ashok-Amin-Joins-Advaxis-bw…
Time & Sales
Price Size Exch Time
$0.1500 300,000 OBB 14:51:31
$0.1500 30,000 OBB 14:49:41
$0.1500 25,000 OBB 14:49:20
$0.1550 10,000 OBB 14:47:33
$0.1550 10,000 OBB 14:47:33
$0.1550 3,000 OBB 14:32:03
$0.1500 17,500 OBB 14:30:27
$0.1500 75,000 OBB 14:30:15
$0.1500 20,300 OBB 14:29:41
$0.1500 5,000 OBB 14:28:27
$0.1500 250 OBB 14:23:44
$0.1500 2,200 OBB 14:23:37
$0.1500 4,000 OBB 14:23:36
$0.1480 1,155 OBB 14:18:18
$0.1500 10,000 OBB 14:10:47
$0.1500 22,000 OBB 14:02:28
$0.1550 1,500 OBB 14:02:22
$0.1510 5,000 OBB 14:01:43
$0.1500 25,000 OBB 14:01:41
$0.1500 13,000 OBB 14:01:40
$0.1500 500 OBB 14:01:40
$0.1500 3,000 OBB 14:01:39
$0.1500 20,000 OBB 14:01:39
$0.1500 2,000 OBB 14:01:38
$0.1500 13,000 OBB 14:01:38
$0.1500 55,000 OBB 14:01:37
$0.1510 5,000 OBB 14:01:33
$0.1510 5,000 OBB 14:01:26
$0.1510 50,000 OBB 13:56:28
$0.1520 77,000 OBB 13:53:52
ein paar schöne Orders heute ................
Price Size Exch Time
$0.1500 300,000 OBB 14:51:31
$0.1500 30,000 OBB 14:49:41
$0.1500 25,000 OBB 14:49:20
$0.1550 10,000 OBB 14:47:33
$0.1550 10,000 OBB 14:47:33
$0.1550 3,000 OBB 14:32:03
$0.1500 17,500 OBB 14:30:27
$0.1500 75,000 OBB 14:30:15
$0.1500 20,300 OBB 14:29:41
$0.1500 5,000 OBB 14:28:27
$0.1500 250 OBB 14:23:44
$0.1500 2,200 OBB 14:23:37
$0.1500 4,000 OBB 14:23:36
$0.1480 1,155 OBB 14:18:18
$0.1500 10,000 OBB 14:10:47
$0.1500 22,000 OBB 14:02:28
$0.1550 1,500 OBB 14:02:22
$0.1510 5,000 OBB 14:01:43
$0.1500 25,000 OBB 14:01:41
$0.1500 13,000 OBB 14:01:40
$0.1500 500 OBB 14:01:40
$0.1500 3,000 OBB 14:01:39
$0.1500 20,000 OBB 14:01:39
$0.1500 2,000 OBB 14:01:38
$0.1500 13,000 OBB 14:01:38
$0.1500 55,000 OBB 14:01:37
$0.1510 5,000 OBB 14:01:33
$0.1510 5,000 OBB 14:01:26
$0.1510 50,000 OBB 13:56:28
$0.1520 77,000 OBB 13:53:52
ein paar schöne Orders heute ................
Antwort auf Beitrag Nr.: 41.832.735 von jacci am 22.07.11 20:41:32Advaxis Revises Protocol for CIN Study
Will Accelerate Enrollment in Mid Dose Leg by up to 5 Months
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia (CIN).
The revised protocol eliminates a staggered dosing design that required two pauses in recruitment to evaluate the safety of all three doses in two successive small groups of patients. The pauses consumed about 5 months in the recently completed low dose cohort that took about 14 months to complete.
The ADXS-HPV CIN study is a randomized, single blind, placebo controlled Phase II dose-ranging study designed to assess the safety and efficacy in up to 3 different dose cohorts.
"We proposed the changes to FDA based on the encouraging safety profile that has emerged after 110 patients have been dosed with ADXS-HPV. This change, combined with the learning curve associated with any clinical study, should bring our mid dose results in much more quickly," commented Advaxis Executive Vice President John Rothman, PhD. "Recruitment for the mid dose cohort is well underway. Our plan continues to be to release the low dose results in early 2012."
About Cervical Intraepithelial Neoplasia (CIN)
CIN is caused by the human papilloma virus and is diagnosed in approximately 500,000 women annually in the US. If left untreated, CIN2/3 is likely to progress to invasive cervical cancer. There is currently no alternative to surgery. Today, there are approximately 250,000 surgical procedures conducted annually to treat CIN 2/3.
About Advaxis, Inc.
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company''s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company''s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad Mir, 609-452-9813
Executive Director
609-452-9818 (FAX)
mir@advaxis.com
or
Diana Moore
Analyst
dmoore@advaxis.com
© 2011 Business Wire
Will Accelerate Enrollment in Mid Dose Leg by up to 5 Months
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia (CIN).
The revised protocol eliminates a staggered dosing design that required two pauses in recruitment to evaluate the safety of all three doses in two successive small groups of patients. The pauses consumed about 5 months in the recently completed low dose cohort that took about 14 months to complete.
The ADXS-HPV CIN study is a randomized, single blind, placebo controlled Phase II dose-ranging study designed to assess the safety and efficacy in up to 3 different dose cohorts.
"We proposed the changes to FDA based on the encouraging safety profile that has emerged after 110 patients have been dosed with ADXS-HPV. This change, combined with the learning curve associated with any clinical study, should bring our mid dose results in much more quickly," commented Advaxis Executive Vice President John Rothman, PhD. "Recruitment for the mid dose cohort is well underway. Our plan continues to be to release the low dose results in early 2012."
About Cervical Intraepithelial Neoplasia (CIN)
CIN is caused by the human papilloma virus and is diagnosed in approximately 500,000 women annually in the US. If left untreated, CIN2/3 is likely to progress to invasive cervical cancer. There is currently no alternative to surgery. Today, there are approximately 250,000 surgical procedures conducted annually to treat CIN 2/3.
About Advaxis, Inc.
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company''s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company''s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad Mir, 609-452-9813
Executive Director
609-452-9818 (FAX)
mir@advaxis.com
or
Diana Moore
Analyst
dmoore@advaxis.com
© 2011 Business Wire
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has received affirmation by the Public Health Service of the U. S. Centers for Disease Control and Prevention (the "CDC") and the Zentrale Kommission für die Biologische Sicherheit (the "ZKBS"), the Central Commission for Biological Safety in Germany, that Advaxis strains, constructs and immunotherapies (the "Advaxis Agents") have been attenuated to the point that they are classified as non-pathogenic materials for handling and shipment. This is not the same as an assessment of safety for medical use by the FDA.
The CDC has determined that Advaxis Agents can be transported into and throughout the U.S. as non-pathogenic consistent with the definition of a Biosafety Level 1 classification (BSL-1), which applies to "well-characterized agents that are not consistently known to cause disease in healthy adult humans and are of minimal potential hazard to laboratory personnel and the environment." Advaxis Agents are manufactured in Germany and the ZKBS has granted them a Risk Group 1 classification (RG1), which are "agents not associated with disease in healthy adult humans." In addition, clinical and/or research sites may submit requests for a ''reduction in containment" from the CDC Office of Biotechnology Activities, which if granted can simplify both laboratory and human clinical handling procedures significantly.
Advaxis Agents can now be transported between production, clinical and/or research sites in the U.S. and Germany without import permits. For additional information on these classifications, please visit these websites: CDC''s glossary of terms, the CDC Biosafety website and Germany''s Federal office for Consumer Protection and Food Safety, Das Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL).
About the U.S. Center for Disease Control
The U.S. Center for Disease Control (CDC) has been dedicated to protecting health and promoting quality of life through the prevention and control of disease, injury and disability. We are committed to programs that reduce the health and economic consequences of the leading causes of death and disability, thereby ensuring a long, productive, healthy life for all people. For more information, please visit their website at http://www.cdc.gov.
About the Zentrale Kommission für die Biologische Sicherheit
The Zentrale Kommission für die Biologische Sicherheit (ZKBS), the German Central Commission for Biological Security, evaluates genetically engineered organisms for their potential impact on humans, animals and the environment. ZKBS scientists are appointed by the Federal Ministry of Food, Agriculture and Consumer Protection. The organization is administered by Das Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL), the Federal office for Consumer Protection and Food Safety. For additional information please visit: the BVL website.
About Advaxis, Inc.
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company''s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company''s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad Mir, 609-452-9813
Executive Director
609-452-9818 (FAX)
mir@advaxis.com
or
Diana Moore, 609-452-9813
Analyst
dmoore@advaxis.com
© 2011 Business Wire
The CDC has determined that Advaxis Agents can be transported into and throughout the U.S. as non-pathogenic consistent with the definition of a Biosafety Level 1 classification (BSL-1), which applies to "well-characterized agents that are not consistently known to cause disease in healthy adult humans and are of minimal potential hazard to laboratory personnel and the environment." Advaxis Agents are manufactured in Germany and the ZKBS has granted them a Risk Group 1 classification (RG1), which are "agents not associated with disease in healthy adult humans." In addition, clinical and/or research sites may submit requests for a ''reduction in containment" from the CDC Office of Biotechnology Activities, which if granted can simplify both laboratory and human clinical handling procedures significantly.
Advaxis Agents can now be transported between production, clinical and/or research sites in the U.S. and Germany without import permits. For additional information on these classifications, please visit these websites: CDC''s glossary of terms, the CDC Biosafety website and Germany''s Federal office for Consumer Protection and Food Safety, Das Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL).
About the U.S. Center for Disease Control
The U.S. Center for Disease Control (CDC) has been dedicated to protecting health and promoting quality of life through the prevention and control of disease, injury and disability. We are committed to programs that reduce the health and economic consequences of the leading causes of death and disability, thereby ensuring a long, productive, healthy life for all people. For more information, please visit their website at http://www.cdc.gov.
About the Zentrale Kommission für die Biologische Sicherheit
The Zentrale Kommission für die Biologische Sicherheit (ZKBS), the German Central Commission for Biological Security, evaluates genetically engineered organisms for their potential impact on humans, animals and the environment. ZKBS scientists are appointed by the Federal Ministry of Food, Agriculture and Consumer Protection. The organization is administered by Das Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL), the Federal office for Consumer Protection and Food Safety. For additional information please visit: the BVL website.
About Advaxis, Inc.
Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor. Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others. Additional information can be found at: advaxis.com | facebook | twitter | LinkedIn
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company''s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company''s actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Advaxis Incorporated
Conrad Mir, 609-452-9813
Executive Director
609-452-9818 (FAX)
mir@advaxis.com
or
Diana Moore, 609-452-9813
Analyst
dmoore@advaxis.com
© 2011 Business Wire
Im Jahr 2011 war der Kurs in der Spitze bei 24 Cent und ich habe nicht verkauft. Dann fiel er ins Bodenlose und jedes Mal wieder schien es mir einfach "ungerecht" dass ich mit Verlust verkaufen sollte. Habe den Wert aus den Augen verloren und auch nicht recherchiert, warum ein Kursverfall von )= % zustande kam.
Seit einigen Monaten bin ich wieder aktiv hier und sehe, dass der Kurs allein in diesem Kalenderjahr gewaltig anzieht. Eigentlich wollte ich meine Depotleichen entfernen, aber so nicht. Mal sehen, was sich findet. Sollte der Malariaimpfstoff endlich der Marktreife näher kommen? Wäre ja eine Sensation. Dann wären die 24 Cent von 2011 gerade mal die Zündung ....
ff
Seit einigen Monaten bin ich wieder aktiv hier und sehe, dass der Kurs allein in diesem Kalenderjahr gewaltig anzieht. Eigentlich wollte ich meine Depotleichen entfernen, aber so nicht. Mal sehen, was sich findet. Sollte der Malariaimpfstoff endlich der Marktreife näher kommen? Wäre ja eine Sensation. Dann wären die 24 Cent von 2011 gerade mal die Zündung ....
ff
Malaria war wohl eine Verwechslung mit Genvec
Die Impfstoffe in der Pipe sind noch weit weg vom Markt, HPV 4 Studien in Phase 2, die anderen präklinisch oder 1. Phase
HPV-Impfstoff gibt es schon in Europa. Warum wird der nicht weltweit verwendet? Und wenn, was sollen dann die neuen Impfstoffe? Habe nicht richtig verstanden, worin deren Vorteil liegen soll. Die Indikation soll nicht die Vorsorge, sondern die Therapie von Krebsartigen Veränderungen durch HPV sein. Ist das der entscheidende Unterschied? Dann wäre es in der Tat ein Knüller.
In der Nachricht vom November hieß es, dass der Impfstoff effektiv und sicher sei, besser als die Standard-Chemo-Therapie mit Cisplatin ...
http://www.news-medical.net/news/20121101/Advaxis-updates-pr…
http://www.advaxis.com/clinical-pipeline/
Ein Teil der Kursbewegungen in den letzten 2 Wochen soll auf Promotion in USA zurück zu führen sein.
http://www.hotstocked.com/article/43212/advaxis-inc-otc-adxs…
Die Impfstoffe in der Pipe sind noch weit weg vom Markt, HPV 4 Studien in Phase 2, die anderen präklinisch oder 1. Phase
HPV-Impfstoff gibt es schon in Europa. Warum wird der nicht weltweit verwendet? Und wenn, was sollen dann die neuen Impfstoffe? Habe nicht richtig verstanden, worin deren Vorteil liegen soll. Die Indikation soll nicht die Vorsorge, sondern die Therapie von Krebsartigen Veränderungen durch HPV sein. Ist das der entscheidende Unterschied? Dann wäre es in der Tat ein Knüller.
In der Nachricht vom November hieß es, dass der Impfstoff effektiv und sicher sei, besser als die Standard-Chemo-Therapie mit Cisplatin ...
http://www.news-medical.net/news/20121101/Advaxis-updates-pr…
http://www.advaxis.com/clinical-pipeline/
Ein Teil der Kursbewegungen in den letzten 2 Wochen soll auf Promotion in USA zurück zu führen sein.
http://www.hotstocked.com/article/43212/advaxis-inc-otc-adxs…
heute wieder über 10 % hoch. Das erfreut mich aber doch. Jetzt sind es noch 300 % zu den alten Höchstständen (zu denen ich NICHT verkauft hatte)
noch 150-160% zu den Höchstständen. Dann ist die Aktie in diesem Kalenderjahr bereits ein Tenbagger.
und jetzt sind es weniger als 100%, die noch fehlen. Ich weiß, das nervt. Aber glaubt mir, mich nervt es auch, dass der Wert so extrem gefallen ist. Dass ich nicht nachgekauft habe, ärgert mich am meisten. Auch wenn klar ist, dass man HINTERHER immer schlauer ist.
Übrigens sind es bis zu meinem Einstand nur noch 20 %
Übrigens sind es bis zu meinem Einstand nur noch 20 %
nun schon 2 Tage mit massiven Abschlägen.
Ist das "nur" eine Korrektur nach 1000% Kursanstieg? Oder war der Anstieg nur ein Zock zum nachhaltigen Abladen?
Ohne News wohl nicht zu beantworten. Da der Anstieg schon begann, bevor es hieß, dass Biotech gekauft werden sollte und sich dann herausstellte, dass Keryx gemeint war, bleibt es noch offen, was hier los ist.
Tatsache ist, dass Advaxis ein tolles Portfoglio hat und schon vor 3 Jahren sehr interessant war. Jetzt sind die schon entsprechend weiter und es gab keine Schreckensnachrichten.
Ist das "nur" eine Korrektur nach 1000% Kursanstieg? Oder war der Anstieg nur ein Zock zum nachhaltigen Abladen?
Ohne News wohl nicht zu beantworten. Da der Anstieg schon begann, bevor es hieß, dass Biotech gekauft werden sollte und sich dann herausstellte, dass Keryx gemeint war, bleibt es noch offen, was hier los ist.
Tatsache ist, dass Advaxis ein tolles Portfoglio hat und schon vor 3 Jahren sehr interessant war. Jetzt sind die schon entsprechend weiter und es gab keine Schreckensnachrichten.
ich habe mich kurzerhand entschieden zu verbilligen und habe ins fallende Messer zu etwa 9 Cent nachgelegt.
Bin glücklich überrascht, dass der Kurs am Freitag kräftig angezogen hat und ich mit den neuen Aktien sogar schon im plus bin.
Für mich könnte das dafür sprechen, dass hier nicht abgeladen wurde, sondern ein größerer Deal anstehen könnte.
Das ist eine unbegründete Spekulation! Somit keine Kaufempfehlung!
Meine Überlegung besteht darin, dass in den letzten Jahren einige Projekte weiter entwickelt wurden, die bereits vor 3 Jahren als sehr aussichtsreich galten und weil im Januar das Gerücht aufkam, dass verschiedene Biotechs übernahmekandidaten sein könnten, wie gerade mit Keryx gesehen.
Bin glücklich überrascht, dass der Kurs am Freitag kräftig angezogen hat und ich mit den neuen Aktien sogar schon im plus bin.
Für mich könnte das dafür sprechen, dass hier nicht abgeladen wurde, sondern ein größerer Deal anstehen könnte.
Das ist eine unbegründete Spekulation! Somit keine Kaufempfehlung!
Meine Überlegung besteht darin, dass in den letzten Jahren einige Projekte weiter entwickelt wurden, die bereits vor 3 Jahren als sehr aussichtsreich galten und weil im Januar das Gerücht aufkam, dass verschiedene Biotechs übernahmekandidaten sein könnten, wie gerade mit Keryx gesehen.
Advaxis (ADXS.OB)
I haven't looked at this company in a while, although it's interesting to see how much this company has moved up since the start of the year.
Advaxis has an important clinical trial catalyst coming up in Q2 2013 (specifically in April). We will be seeing the completion of its phase II trial, which is studying the Listeria Vaccine in CIN 2+ patients. This is ultimately another treatment for cervical cancer that attempts to stop the mechanism by which human papilloma virus (HPV) causes cervical cancer.
I think that the company could definitely have another leg-up on solid results. It seems that recent buying interest in ADXS has been pushing shares up ahead of the release of this phase II cervical cancer trial.
http://seekingalpha.com/article/1142721-4-small-biotechs-wit…
I haven't looked at this company in a while, although it's interesting to see how much this company has moved up since the start of the year.
Advaxis has an important clinical trial catalyst coming up in Q2 2013 (specifically in April). We will be seeing the completion of its phase II trial, which is studying the Listeria Vaccine in CIN 2+ patients. This is ultimately another treatment for cervical cancer that attempts to stop the mechanism by which human papilloma virus (HPV) causes cervical cancer.
I think that the company could definitely have another leg-up on solid results. It seems that recent buying interest in ADXS has been pushing shares up ahead of the release of this phase II cervical cancer trial.
http://seekingalpha.com/article/1142721-4-small-biotechs-wit…
Mit 15 Produkten in der Pipe wird Advaxis es nicht ohne starken Partner schaffen. Bei der kürzlichen Konferenz ging es dann auch darum einen Partner zu finden und nicht um technische Daten.
http://www.siliconinvestor.com/readmsg.aspx?msgid=28653387
Derzeit läuft ein massives Promoting in USA und der Kurs ist schon gewaltig angesprungen. Nichts desto trotz sieht der Chart fantastisch aus. Nach einem tiefen Einbruch kam es indraday zu einem Höchstkurs zu Handelsende und das (Kalender)jahreshoch bei 15 Cent sollte das nächste Ziel sein.
Sollte es gelingen, wenigstens einen Impfstoff zu verpartnern, wird auch das Überleben der Firma gesichert sein. Stellt sich die Frage, ob sie dann nicht gleich gekauft werden. Bei der Pipe wäre ein Kurs unter 1 $ eigentlich unverschämt billig. Aber wegen der Entfernung bis zur Zulassung auch nicht ausgeschlossen.
Ich erwarte / erhoffe Kurse, die aus heutiger Sicht jenseits sind - von Gut und Böse
http://www.siliconinvestor.com/readmsg.aspx?msgid=28653387
Derzeit läuft ein massives Promoting in USA und der Kurs ist schon gewaltig angesprungen. Nichts desto trotz sieht der Chart fantastisch aus. Nach einem tiefen Einbruch kam es indraday zu einem Höchstkurs zu Handelsende und das (Kalender)jahreshoch bei 15 Cent sollte das nächste Ziel sein.
Sollte es gelingen, wenigstens einen Impfstoff zu verpartnern, wird auch das Überleben der Firma gesichert sein. Stellt sich die Frage, ob sie dann nicht gleich gekauft werden. Bei der Pipe wäre ein Kurs unter 1 $ eigentlich unverschämt billig. Aber wegen der Entfernung bis zur Zulassung auch nicht ausgeschlossen.
Ich erwarte / erhoffe Kurse, die aus heutiger Sicht jenseits sind - von Gut und Böse
heutige Meldung auf www.otcbb.com
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Brown University Oncology Research Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. Dr. Howard Safran, professor of medicine, will be principal investigator. Patients will be treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). Multiple institutions will collaborate.
This non-randomized, open-label, multi-center study will evaluate the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer. The primary objectives of the trial include the evaluation of adverse events and the evaluation of 6-month clinical response. The study is expected to open for enrollment February 2013.
“We are pleased that the Brown University Oncology Research Group is coordinating this study in anal cancer using Advaxis’ lead construct ADXS-HPV,” commented Dr. Robert Petit, Vice President of Clinical Operations & Medical Affairs at Advaxis. “This study is an important first step in evaluating the combination of ADXS-HPV immunotherapy with the standard of care in HPV-associated cancers like anal cancer. The investigation of ADXS-HPV across a number of indications and in combination with other therapies will help us learn how best to use Advaxis immunotherapy to benefit patients with HPV-associated cancers. The anal cancer study will continue to build the safety and efficacy profile of our immunotherapy platform.”
Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Brown University Oncology Research Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer. Dr. Howard Safran, professor of medicine, will be principal investigator. Patients will be treated at Rhode Island Hospital and The Miriam Hospital (the main teaching hospitals of The Warren Alpert Medical School of Brown University). Multiple institutions will collaborate.
This non-randomized, open-label, multi-center study will evaluate the safety and effectiveness of ADXS-HPV when combined with standard chemotherapy and radiation treatment for anal cancer. The primary objectives of the trial include the evaluation of adverse events and the evaluation of 6-month clinical response. The study is expected to open for enrollment February 2013.
“We are pleased that the Brown University Oncology Research Group is coordinating this study in anal cancer using Advaxis’ lead construct ADXS-HPV,” commented Dr. Robert Petit, Vice President of Clinical Operations & Medical Affairs at Advaxis. “This study is an important first step in evaluating the combination of ADXS-HPV immunotherapy with the standard of care in HPV-associated cancers like anal cancer. The investigation of ADXS-HPV across a number of indications and in combination with other therapies will help us learn how best to use Advaxis immunotherapy to benefit patients with HPV-associated cancers. The anal cancer study will continue to build the safety and efficacy profile of our immunotherapy platform.”
nach neueren Recherchen komme ich zu der Schlussfolgerung, dass das hier alles doch nicht seriöus ist. Die gleichen Studienansagen wie vor 3 Jahren, einfach kein Fortschritt und auf Internetseiten, die sich auf Biotech-Info spezialisiert haben sind die letzten Studienangaben schon uralt. Auch der Wortlaut in der letzten Meldung wurde schon einmal verwendet.
Kann sein, dass der Wert noch ein Stück weit hochgezogen wird, vielleicht 16 Cent. Immerhin steigt er an einem Tag wie heute, wohl auch deshalb weil mit den seriöusn Aktien zur Zeit kein Geld zu verdienen ist.
Ich habe die steigenden Kurse zum Ausstieg genutzt, obwohl ich damit kleine Verluste realisieren musste.
Habe derzeit von Börse und Co die Nase so voll, dass ich mich auf 2 Sondersituationen beschränke und ansonsten komplett zurück ziehe.
Kann sein, dass der Wert noch ein Stück weit hochgezogen wird, vielleicht 16 Cent. Immerhin steigt er an einem Tag wie heute, wohl auch deshalb weil mit den seriöusn Aktien zur Zeit kein Geld zu verdienen ist.
Ich habe die steigenden Kurse zum Ausstieg genutzt, obwohl ich damit kleine Verluste realisieren musste.
Habe derzeit von Börse und Co die Nase so voll, dass ich mich auf 2 Sondersituationen beschränke und ansonsten komplett zurück ziehe.
heute wird ein Reverse-Split 1:125 angekündigt. Wie ist das zu beurteilen?
Man käme damit auf einen Kurs oberhalb eines $ und könnte das Segment wechseln. Das wäre nur sinnvoll, wenn doch endlich Resultate anständen.
Oder alles nur bluff?
Man käme damit auf einen Kurs oberhalb eines $ und könnte das Segment wechseln. Das wäre nur sinnvoll, wenn doch endlich Resultate anständen.
Oder alles nur bluff?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 71 | ||
| 54 | ||
| 47 | ||
| 46 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 15 | ||
| 13 | ||
| 12 |
| Wertpapier | Beiträge | |
|---|---|---|
| 12 | ||
| 11 | ||
| 11 | ||
| 10 | ||
| 10 | ||
| 10 | ||
| 10 | ||
| 9 | ||
| 9 | ||
| 9 |
